U.S. medical firm Allergan Inc rejected the unsolicited takeover offer from Valeant Pharmaceuticals International Inc , saying it substantially undervalued the company.Canada's Valeant said on April 22 that it and activist investor Bill Ackman made an unsolicited $47 billion bid to purchase Allergan.Allergan, which makes the popular anti-wrinkle treatment Botox, also said on Monday it expected to increase its earnings per share by 20-25 percent and continue to generate double digit revenue growth in 2015.
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN fell by 1.3% or $-2.13/share to $161.30. In the past year, the shares have traded as low as $81.33 and as high as $170.05. On average, 3978680 shares of AGN exchange hands on a given day and today's volume is recorded at 4569150.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $131.17. In the past year, the shares have traded as low as $73.25 and as high as $153.10. On average, 2662840 shares of VRX exchange hands on a given day and today's volume is recorded at 3023480.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.63% or $0.89/share to $142.96. In the past year, the shares have traded as low as $73.24 and as high as $170.45. On average, 384857 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 204891.
Source
